Sale!

COL11A2 Gene Deafness Autosomal Recessive Type 53 Genetic Test

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The COL11A2 gene is associated with a rare form of non-syndromic hearing loss known as Deafness, Autosomal Recessive Type 53 (DFNB53). This condition is characterized by a mutation in the COL11A2 gene, which plays a crucial role in the production of type XI collagen, a protein essential for the proper development and maintenance of the inner ear structure. Individuals with mutations in this gene may experience mild to profound hearing loss, typically present from birth.

To diagnose this specific type of genetic deafness, a targeted genetic test is available at DNA Labs UAE. This test specifically looks for mutations in the COL11A2 gene that are known to cause Deafness, Autosomal Recessive Type 53. The test is crucial for early diagnosis, which can significantly impact the management and treatment options for affected individuals, potentially improving their quality of life.

The cost of the COL11A2 Gene Deafness Autosomal Recessive Type 53 Genetic Test at DNA Labs UAE is 4400 AED. This test is a valuable resource for families with a history of hearing loss or for newborns who fail initial hearing screenings. Early genetic diagnosis through this test can facilitate prompt intervention services and genetic counseling for families, guiding them through understanding the condition and planning for the future.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

COL11A2 Gene Deafness Autosomal Recessive Type 53 Genetic Test

Are you concerned about your hearing? Do you suspect that you may have COL11A2 gene deafness autosomal recessive type 53 (DFNB53)? DNA Labs UAE offers a comprehensive genetic test that can provide answers.

Test Components

The COL11A2 Gene Deafness Autosomal Recessive Type 53 Genetic Test includes:

  • NGS Technology
  • Ear Nose Throat Disorders
  • ENT Doctor
  • Genetics Department

Price

The cost of the COL11A2 Gene Deafness Autosomal Recessive Type 53 Genetic Test is AED 4400.0.

Sample Condition

We accept the following sample conditions for testing:

  • Blood
  • Extracted DNA
  • One drop of blood on FTA Card

Report Delivery

Once the sample is received, the report will be delivered within 3 to 4 weeks.

Method

We use NGS (Next-Generation Sequencing) technology for the COL11A2 Gene Deafness Autosomal Recessive Type 53 Genetic Test.

Test Type

The test is specifically designed to diagnose and analyze Ear Nose Throat Disorders.

Doctor

The test is conducted by an ENT Doctor who specializes in genetic testing.

Pre Test Information

Prior to the test, it is important to provide the clinical history of the patient. This is especially crucial for individuals who are going for the CATSPER2 Gene Deafness and male infertility, CATSPER2 related NGS Genetic DNA Test. A Genetic Counselling session will be conducted to draw a pedigree chart of family members affected with CATSPER2 Gene Deafness and male infertility, CATSPER2 related NGS Genetic DNA Test gene CATSPER10.

Test Details

The COL11A2 gene is associated with a type of deafness known as autosomal recessive type 53 (DFNB53). This means that individuals with two copies of a mutated COL11A2 gene will have this type of deafness.

NGS (Next-Generation Sequencing) genetic testing allows for the simultaneous sequencing of multiple genes or even the entire genome. In the case of COL11A2 gene deafness, NGS genetic testing can be used to identify mutations or variations in the COL11A2 gene that may be responsible for causing DFNB53.

The process involves extracting DNA from a patient’s sample (such as blood or saliva), sequencing the DNA using advanced sequencing technologies, and then analyzing the data to identify any mutations or variations in the COL11A2 gene.

By identifying mutations in the COL11A2 gene, NGS genetic testing can help diagnose individuals with DFNB53 and provide information about the genetic cause of their deafness. This can be valuable for understanding the inheritance pattern of the condition within a family and for making informed decisions regarding family planning or potential treatment options.

Test Name COL11A2 Gene Deafness autosomal recessive type 53 Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Ear Nose Throat Disorders
Doctor ENT Doctor
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for CATSPER2 Gene Deafness and male infertility, CATSPER2 related NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with CATSPER2 Gene Deafness and male infertility, CATSPER2 related NGS Genetic DNA Test gene CATSPER10
Test Details

The COL11A2 gene is associated with a type of deafness known as autosomal recessive type 53 (DFNB53). This means that individuals with two copies of a mutated COL11A2 gene will have this type of deafness.

NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that allows for the simultaneous sequencing of multiple genes or even the entire genome. In the case of COL11A2 gene deafness, NGS genetic testing can be used to identify mutations or variations in the COL11A2 gene that may be responsible for causing DFNB53.

NGS genetic testing involves extracting DNA from a patient’s sample (such as blood or saliva), sequencing the DNA using advanced sequencing technologies, and then analyzing the data to identify any mutations or variations in the COL11A2 gene.

By identifying mutations in the COL11A2 gene, NGS genetic testing can help diagnose individuals with DFNB53 and provide information about the genetic cause of their deafness. This can be valuable for understanding the inheritance pattern of the condition within a family and for making informed decisions regarding family planning or potential treatment options.